New patent strengthens the AroCell patent portfolio

The European Patent Office has confirmed the grant of a patent to AroCell AB regarding an invention relating to exposed thymidine kinase 1 (TK1) derived peptides, ligands and methods employing these.

“We are delighted to hear that the European Patent Office has granted us this patent regarding exposed proliferation related peptides”, states Jan Stålemark, AroCell CEO. “This latest patent provides us with an additional level of protection for our unique TK 210 ELISA test, as we continue to establish the clinical validation of our product”.

For further information:

Jan Stålemark, CEO
AroCell AB (pub)
Tel: +46-706926206

info@arocell.com
www.arocell.com

 

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell AB is listed at AktieTorget (AROC) and has about 2 300 shareholders.

This press release in English, PDF
This press release in Swedish, PDF